Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 6/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.46 |
| ▸ | HSPA8 | P11142 | 4/20 | 0.46 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAPDH | P04406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21368888 | 0.87 | ADK (0.51) | ADKHSPA8HSPA5RXFP1SLC28A2 | |
| SCHEMBL21368889 | 0.85 | CDK5 (0.59) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL21368800 | 0.84 | ADK (0.52) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL21368890 | 0.84 | ADK (0.48) | ADKHSPA8HSPA5RXFP1HSD17B10 | |
| SCHEMBL23809777 | 0.81 | ADK (0.46) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL21369233 | 0.81 | ADK (0.46) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL19837972 | 0.81 | ADK (0.67) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL19837987 | 0.80 | ADK (0.67) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL21351731 | 0.80 | ADK (0.67) | ADKSLC29A1HSPA8HSPA5RXFP1 | |
| SCHEMBL21368891 | 0.80 | ADK (0.73) | ADKSLC29A1HSPA8HSPA5HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765475-B1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2021-09-15 | — | — | EP | disclosed |
| US-20210002321-A1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2021-01-07 | — | — | US | disclosed |
| WO-2019174657-A1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002321-A1 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | TYMP, DPYD, RRM2 | ADK 539/4885SLC29A1 147/4885HSPA8 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.